Michael Lee Brooks - 02 Mar 2022 Form 4 Insider Report for Syneos Health, Inc.

Role
Chief Development Officer & Global Head Clinical Development Solutions
Signature
/s/ Sara Epstein, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
02 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Mar 2022, 16:03:50 UTC
Previous filing
18 Feb 2022
Next filing
18 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYNH Class A Common Stock Award $0 +1,324 +3.7% $0.000000 36,777 02 Mar 2022 Direct F1
holding SYNH Class A Common Stock 10,842 02 Mar 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2021 and will vest in full once the Compensation and Management Development Committee of the Board of Directors of Syneos Health, Inc. determines the attainment level of the performance goals for the year ended December 31, 2023, subject to continued employment.

Remarks:

Chief Development Officer & Global Head Clinical Development Solutions